We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Learn about Luminal B breast cancer, a specific subtype characterized by hormone receptor positivity and high Ki-67 levels. Understand its symptoms, diagnosis, treatment options, and outlook.

Imagine your breast cancer as a specific type, like a fingerprint. That's essentially what a molecular subtype is. Luminal B breast cancer is one such fingerprint, a specific kind of breast cancer that doctors identify through detailed tests. It's part of a larger classification system that helps doctors understand how aggressive a cancer might be and how it might respond to different treatments. In India, as across the world, understanding these subtypes is key to tailoring the best possible care for each patient.
Breast cancer isn't just one disease; it's a group of diseases. Doctors classify breast cancers into different types based on the characteristics of the cancer cells themselves. One of the most common ways they do this is by looking at certain proteins on the surface of the cancer cells and inside them. These include hormone receptors (like estrogen and progesterone receptors) and a protein called HER2. Luminal B breast cancer is defined by a specific combination of these markers.
Specifically, Luminal B breast cancer is hormone receptor (HR)-positive. This means the cancer cells have receptors that can bind to estrogen and/or progesterone, hormones that are naturally present in the body. These hormones can fuel the growth of these cancer cells. Additionally, Luminal B can be either HER2-positive or HER2-negative. HER2 (human epidermal growth factor receptor 2) is a protein that can also promote cancer cell growth. Finally, a hallmark of Luminal B is a high level of a protein called Ki-67. Ki-67 is a marker of cell proliferation, meaning it tells us how quickly the cancer cells are dividing and growing. A high Ki-67 level indicates that the cancer cells are dividing rapidly, which usually means the cancer is more aggressive.
To put this in perspective, there are four main molecular subtypes of breast cancer:
So, Luminal B stands out because it's hormone-driven, potentially HER2-driven, and fast-growing. This combination means it often requires a more robust treatment approach compared to Luminal A breast cancer.
It's vital to remember that the symptoms of Luminal B breast cancer are generally the same as those for other types of breast cancer. Early detection is always the best strategy, and knowing what to look for can make a significant difference. Don't ignore any changes in your breasts; they are your body's way of telling you something needs attention.
Common signs and symptoms include:
Important Note: Many of these symptoms can also be caused by non-cancerous conditions. However, if you experience any of these changes, it's essential to see a doctor promptly. Self-examination is good, but professional medical evaluation is non-negotiable.
Pinpointing Luminal B breast cancer involves a series of diagnostic steps. Doctors need to understand the specific biological makeup of the tumor to plan the most effective treatment. This isn't just about finding a lump; it's about understanding its 'personality'.
The diagnostic process typically starts with:
Based on these results, your doctor can classify the breast cancer, including identifying it as Luminal B, and then discuss the best course of action.
Treatment for Luminal B breast cancer is carefully planned and often involves a combination of therapies. Because it's hormone-driven and can be fast-growing, treatment aims to block the hormones that feed the cancer and eliminate the rapidly dividing cells.
Common treatment modalities include:
The exact treatment plan will depend on many factors, including the stage of the cancer, the patient's age, menopausal status, overall health, and personal preferences. Your oncologist will discuss all these options thoroughly with you.
The outlook for Luminal B breast cancer has improved significantly with advancements in treatment. While it's considered more aggressive than Luminal A, the availability of effective hormone therapies and, if applicable, HER2-targeted treatments, has led to better outcomes. Early diagnosis and adherence to the treatment plan are paramount. Regular follow-ups with your doctor are essential to monitor for recurrence and manage any long-term side effects.
If you notice any changes in your breasts, such as a new lump, skin changes, nipple discharge, or a change in size or shape, do not delay. Schedule an appointment with your doctor immediately. Also, if you have a family history of breast cancer or have concerns about your risk, speak with your doctor about appropriate screening schedules.
A breast cancer diagnosis can be overwhelming. In India, numerous resources and support systems are available to help patients and their families navigate this journey. Connecting with support groups can provide emotional strength and practical advice. Organizations like the Indian Cancer Society, Cancer Patients Aid Association (CPAA), and various hospital-based support groups offer valuable assistance.
Remember, you are not alone. Early detection, accurate diagnosis, and personalized treatment are key to managing Luminal B breast cancer effectively. Stay informed, stay hopeful, and work closely with your healthcare team.
Learn about potential side effects of CML treatments like TKIs, interferon, chemotherapy, and stem cell transplants. Understand what to expect and how to communicate with your doctor for effective management.
April 1, 2026

Discover essential support resources, financial aid options, and community connections for individuals navigating life with Chronic Myeloid Leukemia (CML). Find practical advice and empathetic guidance.
April 1, 2026
Explore targeted therapy for multiple myeloma. Learn how these precision treatments work, their types, potential side effects, and how they're used alongside other therapies to manage this blood cancer.
April 1, 2026